Compare McKesson Corporation (MCK) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Nomura Holdings Inc — how do they compare? McKesson Corporation trades at $824 (market cap $97.35B), while Nomura Holdings Inc trades at $9.8 (market cap $27.46B). The key difference: McKesson Corporation is far larger — about 3.5× Nomura Holdings Inc's market cap, and Nomura Holdings Inc pays the higher dividend (3.45%). Which is the better fit depends on your goals.
| MCK | NMR | |
|---|---|---|
Market Cap | $97.35B | $27.46B |
Sector | Health | Financials |
52-Week High | $995.69 | $10.04 |
52-Week Low | $659.01 | $6.39 |
Enterprise Value | $101.98B | — |
Dividend Yield | 0.39% | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Nomura Holdings (NMR) trades at $9.395, down 0.05% on the day, with a bullish technical signal from moving averages. The company reported record annual net income of $340.74 billion for 2025, with a net income margin of 20.49%, while revenue grew to $1.66 trillion. Recent news highlights strong wholesale revenue momentum and strategic acquisitions, including a U.S. fund management expansion. The stock shows a P/E of 12.78 and P/B of 1.2, indicating potential value relative to earnings.
The outlook for NMR is supported by earnings growth and strategic initiatives, but risks include volatile cash flows and rising debt levels. Analyst consensus is mixed with 33% buy ratings, suggesting cautious optimism. Further upside depends on sustained profitability and successful integration of recent acquisitions amid competitive and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
